Clinical Trial Update: The Efficacy and Safety of Neoadjuvant Therapy With Iparomlimab and Tuvonralimab in Locally Advanced MSI-H/dMMR Colorectal Cancer: An Prospective, Single-Arm Study (Neo-IT) [Phase 2]

View source ↗

Summary

Phase 2 neoadjuvant trial evaluating the immune therapies iparomlimab and tuvonralimab in locally advanced dMMR/MSI-H rectal adenocarcinoma; the study is curren…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rectal Adenocarcinoma

Drugs mentioned

• Tuvonralimab (tuvonralimab)
• iparomlimab

Snippet

Sponsor: Sir Run Run Shaw Hospital | Conditions: dMMR/MSI-H-type Rectal Adenocarcinoma | Phase 2 | Status: ACTIVE_NOT_RECRUITING